Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marillion Pharmaceuticals, a clinical-stage pharmaceuticals company, and Bracco Imaging, a diagnostic imaging company and part of the Bracco Group, have entered into a licensing agreement granting Marillion exclusive worldwide rights to complete clinical development and to commercialize Bracco's 177Lu-AMBA for the treatment of hormone-resistant prostate and advanced breast cancers.
Subscribe to our email newsletter
Zahed Subhan, CEO of Marillion Pharmaceuticals, said: “177Lu-AMBA is a targeted radiotherapeutic that utilizes an innovative receptor-based technology. In contrast to traditional modes of treatment for advanced cancers, this unique targeting capability means that 177Lu-AMBA is able to home in on tumor cells and spare normal tissues.
“In addition, up to 70% of patients with prostate cancer have bone metastases which cause unrelenting pain. Early clinical trials have shown that these metastases may also be effectively targeted by 177Lu-AMBA.”